China News Service, Beijing, July 23 (Reporter Li Chun) Feng Zijian, executive vice president and secretary-general of the Chinese Preventive Medicine Association, said at the press conference of the joint prevention and control mechanism on the 23rd that the research and development of the Omi-Kron variant vaccine in China is steadily progressing To promote, as long as there is a need, in accordance with relevant regulations, the approval process for emergency use can be quickly started to provide vaccination.
Feng Zijian said that from December 26, 2021, that is, the day after the World Health Organization listed the Omicron variant as a variant of concern, experts will be organized to judge and deploy. Research and development work, at present, a number of technical routes have carried out the research and development of monovalent and multivalent Omicron variant vaccines.
He introduced that the fast-moving monovalent Omicron variant inactivated vaccine has been approved for clinical trials, and clinical trials are being carried out in Zhejiang, Hunan, Hong Kong and other places, and the fast-moving quadrivalent recombinant protein vaccine has obtained Phase III clinical trials in the United Arab Emirates Trial approval, related research has been started, and other monovalent and multivalent inactivated vaccines containing Omicron mutants, recombinant protein vaccines, adenovirus vector vaccines, and mRNA vaccines are also conducting preclinical research, and those with faster progress have been developed. The Drug Approval Center submits the clinical trial application materials.
In addition, the special class has also deployed research on broad-spectrum new crown vaccines, and vaccines that are progressing faster have obtained clinical trial approvals and started related research.
"In general, the research and development of the Omicron variant vaccine in China is progressing steadily. As long as there is a need, in accordance with relevant regulations, the approval process for emergency use can be quickly started to provide vaccination." Feng Zijian said, as for whether vaccination is required, When to vaccinate vaccines containing Omicron mutants, this issue is not only being studied in China, but also internationally, mainly to determine the situation of virus mutation and immune escape.
Feng Zijian also said that the results of a number of studies show that the effect of existing vaccines at home and abroad in preventing severe illness and death still maintains a high level.
The Chinese vaccine still has a good protective effect against severe illness and death caused by the Omicron variant, and boosting immunity can further reduce the risk of hospitalization, severe illness and death.
He also cited real-world studies on the preventive effects of domestic vaccines vaccinated in Hong Kong and the mainland, showing that the protective effects of existing vaccines against severe illness and death are still good.
A study published by the University of Hong Kong showed that the protective effect of two doses of domestic inactivated vaccine for the elderly over 60 years old was 69.9% in preventing severe illness and death. 97.9%.
(Finish)